Clinical Trial Update: XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of XL092 (Zanzalintinib) for metastatic or unresectable leiomyosarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma

Drugs mentioned

• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Northwestern University | Conditions: Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Status: RECRUITING